IL294486A - Antibodies against gal3 and methods of use - Google Patents

Antibodies against gal3 and methods of use

Info

Publication number
IL294486A
IL294486A IL294486A IL29448622A IL294486A IL 294486 A IL294486 A IL 294486A IL 294486 A IL294486 A IL 294486A IL 29448622 A IL29448622 A IL 29448622A IL 294486 A IL294486 A IL 294486A
Authority
IL
Israel
Prior art keywords
seq
cdr2
cdr3
cdr1
chain variable
Prior art date
Application number
IL294486A
Other languages
English (en)
Hebrew (he)
Inventor
Dongxu Sun
Suhail Rasool
Catherine A Gordon
Ke Hong
Fan Chen
Sara Matilda Bolin
Ksenya Shchors
Yadong Yu
Tsung-Huang Tsai
Samuel A F Williams
Karan Lala
Heng Wu
Yan Wang
Original Assignee
Truebinding Inc
Dongxu Sun
Suhail Rasool
Catherine A Gordon
Ke Hong
Fan Chen
Sara Matilda Bolin
Ksenya Shchors
Yadong Yu
Tsai Tsung Huang
Samuel A F Williams
Karan Lala
Heng Wu
Yan Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Truebinding Inc, Dongxu Sun, Suhail Rasool, Catherine A Gordon, Ke Hong, Fan Chen, Sara Matilda Bolin, Ksenya Shchors, Yadong Yu, Tsai Tsung Huang, Samuel A F Williams, Karan Lala, Heng Wu, Yan Wang filed Critical Truebinding Inc
Publication of IL294486A publication Critical patent/IL294486A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
IL294486A 2020-01-13 2021-01-12 Antibodies against gal3 and methods of use IL294486A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062960300P 2020-01-13 2020-01-13
US202063024327P 2020-05-13 2020-05-13
US202063092069P 2020-10-15 2020-10-15
US202063122409P 2020-12-07 2020-12-07
PCT/US2021/013136 WO2021146218A1 (en) 2020-01-13 2021-01-12 Anti-gal3 antibodies and methods of use

Publications (1)

Publication Number Publication Date
IL294486A true IL294486A (en) 2022-09-01

Family

ID=76864188

Family Applications (1)

Application Number Title Priority Date Filing Date
IL294486A IL294486A (en) 2020-01-13 2021-01-12 Antibodies against gal3 and methods of use

Country Status (11)

Country Link
US (2) US20230036181A1 (enExample)
EP (1) EP4090685A4 (enExample)
JP (2) JP2023510866A (enExample)
KR (1) KR20220129030A (enExample)
CN (2) CN119930824A (enExample)
AU (1) AU2021207461A1 (enExample)
BR (1) BR112022013892A2 (enExample)
CA (1) CA3166552A1 (enExample)
IL (1) IL294486A (enExample)
MX (1) MX2022008450A (enExample)
WO (1) WO2021146218A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) * 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
CN115279789A (zh) * 2019-12-06 2022-11-01 真和制药有限公司 破坏gal3和胰岛素受体或整联蛋白的相互作用的抗体及其使用方法
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
JP2024526764A (ja) * 2021-07-13 2024-07-19 トゥルーバインディング，インコーポレイテッド タンパク質凝集を防止する方法
US20230279120A1 (en) * 2021-11-09 2023-09-07 Truebinding, Inc. Methods of treating or inhibiting cardiovascular diseases
WO2024073511A2 (en) * 2022-09-28 2024-04-04 Truebinding, Inc. Therapies with anti-gal3 antibodies
JP2026523670A (ja) * 2024-03-08 2026-07-14 サンメッド セラピューティック リミテッド 抗ガレクチン３抗体ならびに癲癇および関連疾患におけるその使用
CN118286392A (zh) * 2024-03-28 2024-07-05 广州医科大学附属妇女儿童医疗中心 重组Galectin-3在治疗慢性炎性脱髓鞘性多发性神经根神经病中的应用
WO2025240949A1 (en) * 2024-05-17 2025-11-20 The Administrators Of The Tulane Educational Fund Compositions and methods for the treatment of idiopathic pulmonary fibrosis
WO2025264872A1 (en) * 2024-06-21 2025-12-26 Truebinding, Inc. Methods and compositions for treating neurodevelopmental disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101222281B1 (ko) * 2004-03-29 2013-01-28 가르파마 컴퍼니 리미티드 신규 갈렉틴 9 개변체 단백질 및 그 용도
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
MX2010005282A (es) * 2007-11-13 2010-08-31 Teva Pharma Anticuerpos humanizados contra tl1a.
US8349579B2 (en) * 2007-12-13 2013-01-08 Wayne State University Galectin-3 cleavage as a marker for matrix metalloproteinase activity in cancer
BRPI0919975A2 (pt) * 2008-10-29 2015-12-15 Bg Medicine Inc imunoensaio para galectina-3
CN103443125B (zh) * 2010-11-30 2019-05-03 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
AU2014370393B2 (en) * 2013-12-27 2018-09-20 Eliaz Therapeutics, Inc. Plasmapheresis device
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN111201030B (zh) * 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
JP7539834B2 (ja) * 2018-02-01 2024-08-26 メモリアル スローン ケタリング キャンサー センター ガレクチン－３に対する抗体及びその使用方法
WO2019165421A1 (en) * 2018-02-26 2019-08-29 Minerva Biotechnologies Corporation Diagnostic methods using anti-muc1* antibodies
KR20210124308A (ko) * 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도

Also Published As

Publication number Publication date
JP2025163070A (ja) 2025-10-28
KR20220129030A (ko) 2022-09-22
AU2021207461A1 (en) 2022-09-01
CN119930824A (zh) 2025-05-06
EP4090685A1 (en) 2022-11-23
US20250145722A1 (en) 2025-05-08
WO2021146218A1 (en) 2021-07-22
BR112022013892A2 (pt) 2022-10-04
CN115427449A (zh) 2022-12-02
US20230036181A1 (en) 2023-02-02
MX2022008450A (es) 2022-12-13
EP4090685A4 (en) 2024-12-18
CA3166552A1 (en) 2021-07-22
JP2023510866A (ja) 2023-03-15

Similar Documents

Publication Publication Date Title
JP7419434B2 (ja) 新規のポリペプチド
JP7578938B2 (ja) Ｂ７－ｈ３に対するモノクローナル抗体および細胞治療におけるその使用
AU2022252753B2 (en) ANTIBODIES TO a-SYNUCLEIN AND USES THEREOF
JP2023510866A5 (enExample)
TWI731310B (zh) 結合檢查點阻礙物作為標的治療的雙功能性蛋白質、其藥物複合體、其醫藥組成物、其核酸、及其用途
CN106687478B (zh) 新的抗人Tie-2抗体
WO2017042210A1 (en) Antibodies having specificity to nectin-4 and uses thereof
JP2017504578A (ja) ｇｐＡ３３及びＣＤ３に結合二重特異性１価ダイアボディ、並びにその使用
KR20160062167A (ko) 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도
CN119930824A (zh) 抗Gal3抗体和使用方法
US20240018204A1 (en) Fusion molecule having non-inflammatory phagocytosis inducing activity
CN117843789A (zh) 治疗性抗cd40配体抗体
WO2024125417A9 (en) Bispecific antibodies targeting pd1 and vegf
CN114981307A (zh) 抗btla抗体药物组合物及其用途
JP6865581B2 (ja) 神経学的疾患又は神経変性疾患に有用な新規抗体
CN117083301A (zh) 特异性识别磷脂酰肌醇蛋白聚糖3的单克隆抗体及其应用
CN116829183A (zh) 施用治疗剂量的双特异性t细胞接合分子治疗癌症的方法
EP3880248A1 (en) Multimeric hybrid fc proteins for replacement of ivig
WO2024238950A1 (en) Methods of using activin receptor type ii variants
JP2023504733A (ja) 抗ｃｌｅｃ－１ａ抗体及びその抗原結合性断片
CN120603850A (zh) 抗cmet抗体及使用方法
JP2025520692A (ja) 抗ｓｌｃ３４ａ２モノクローナル抗体およびその使用
Gaindh et al. Prolonged beneficial effect of brief erythropoietin peptide JM4 therapy on chronic relapsing EAE
WO2024188331A1 (zh) 一种含pd-1/pvrig/tigit结合蛋白的药物组合物及其医药用途
WO2023186113A9 (zh) 靶向pd-l1和cd40的抗原结合蛋白及其制备和应用